imig2014 Cape Town Final Scientific Programme 21-24 October 2014

imig2014 Cape Town Final Scientific Programme 21-24 October 2014 Day 0-21 October 2014 Welcome to Cape Town! Registrati Welcome Cocktails 1500 1800 Cape Town Internatial Cference Centre Cape Town Internatial Cference Centre 00.1 Dr T Makgoba 1900 Welcome to Cape Town and South Africa Dear Colleagues, imig 2014 in Cape Town will be host to 160+ high quality oral presentatis, about 30 poster discussis and around 150 posters. The morning sessis starting at 08:00 will be 2 hours and the afterno sessis 1½ hours in durati. Poster discussis will occur at 17:00 Days 1 and 2, with poster viewings throughout the day the first two days. Except for the plenary sessis, each oral presentati will be 15 minutes, to be strictly enforced by the Chairs armed with vuvuzela s. The weather for 21-24 October will be mostly sunny, with temperatures ranging from 13-21 C (55-70 F). Please pack a light rain jacket if you are venturing out, as Cape Town and Cape Peninsula weather can be unpredictable. We look forward to a very good meeting over the next 3 days, and to furthering our comm quest for preventi and cure. Sincerely, Jim tewaternaude

Day 1-22 October 2014 10 Registrati Opening Plenary 0700 0800 S Mutsaers Invited Speakers appear in Bold J tewaternaude 10.1 C Alifrangis 0815 Next Generati Sequencing: Genome-Directed Precisi Medicine in 10.2 R Salgia 0840 --From Chaos to Mitochdrial Functiality: What the Fractal? 10.3 R Weinberg 0905 imig Special Keynote Lecture: Cancer Stem Cells as Target Pathways 10.4 L Kazan-Allen 0930 The Global Asbestos Landscape: Past, Present and Future 1000 Coffee/Poster Viewing 11 Epidemiology 1 1030 J Peto 12 Immunotherapy 1030 A Nowak 13 Optimising Surgery 1030 W Vigneswaran R Ehrlich D Sterman I Opitz 11.1 J Peto 1030 Anti-Mesothelin Vaccine CRS-207 Plus Worldwide Epidemiology of 12.1 R Hassan 1030 Chemotherapy as Frt-Line Treatment for MPM 13.1 D Waller 1030 P/D: The Best There Is? 11.2 G Nels 1045 11.3 F Baumann 1100 11.4 C Magnani 1115 11.5 J Murray 1130 11.6 M Mencobi 1145 11.7 M Metintas 1200 The Burden of in an Asbestos-Exposed Cohort: The MINKS Study Epidemiological Indicators of an Envirmental Exposure to Asbestos-Like Carcinogenic Fibers: Methodological Issues Malignant after Exposure to Chrysotile in Balangero, Italy: An Update Clinicopathological Correlati of Asbestos-Related Diseases in Former Miners Clinicopathological Features of Patients with Malignant in a Multicenter, Retrospective Study Identificati of Variables Affecting Malignant : An Ecologic Study 12.2 A Cook 1045 12.3 J Aerts 1100 12.4 E Mo 1115 12.5 L Calabro 1130 12.6 S Anguille 1145 12.7 E Mo 1200 A Phase Ib Clinical Trial of the CD40 Activating Antibody CP-870,893 in Combinati with Cisplatin and Pemetrexed in MPM Dendritic Cell-Based Vaccinati under Reduced Tumor-Induced Immune Suppressi in MPM Targeting Tumor Stroma of with Chimeric Antigen Receptor T Cells Tremelimumab at an Optimized Dosing Schedule in Secd-Line Patients: A Phase II Single-Arm Study Survival Advantage Following Dendritic Cell Vaccine Therapy in MPM: A Phase I/II Clinical Trial A Phase I Clinical Trial of Anti- Mesothelin mrna Chimeric Antigen Receptor T-Cell Therapy in Patients 13.2 J van Meerbeeck 1045 13.3 J Steele 1100 13.4 E Ruffini 1115 13.5 H Fevzi Batirel 1130 13.6 A Sharkey 1145 13.7 Chairs 1200 European Surgical Trials: MARS2 vs. EORTC After Surgical Treatment: A Critical Appraisal Multiple-Variable Adjusted Prognostic Model for Optimal Surgical Approach to MPM: A Clinicopathological Analysis 167 Patients Surgery after MARS Trial: Does Change in Surgical Technique Affect Survival Outcomes? The Effects of an Intential Transiti from Extrapleural Pneumectomy to Extended Pleurectomy/Decorticati Discussi: How Should We Select Surgical Patients Today and How Will We Select Them in Five Years?

11.8 Chairs 1215 Discussi 12.8 H Kindler 1215 with Progressive MPM PD-1: Integrating Immune Checkpoint Modulati into Therapy for MM 13.8 Chairs 1215 Discussi 14 Animal Models & Preclinical Studies 14.1 H Yang 1330 14.2 S Lansley 1345 14.3 R Lake 1400 14.4 R Lake 1415 14.5 A Nowak 1430 1230 Lunch/Poster Viewing 1230 Lunch/Poster Viewing 1230 Lunch/Poster Viewing 1330 D Barbe 15 Periteal 1330 E Choi 16 Surgery Symposium 1330 W Weder R Lake M Deraco J Friedberg Periteal : Overcome Aspirin Delays the Limits of Chemotherapy and Growth by Targeting High- 15.1 M Deraco 1330 16.1 D 1330 Optimize the Results of the CRS-HIPEC Sugarbaker Mobility Group Box 1 Protein through Translatial Research Fibroblast Growth Factor Receptor (FGFR) Inhibitors Significantly Retard Tumour Growth in Two Orthotopic Murine Models of Statins Do Not Alter the Incidence of in Asbestos-Exposed Mice or Humans Aspirin Has No Significant Effect Asbestos-Induced in MexTAg Mice Csistent with Data from a Human Cohort Imaging and Modulating Hypoxia in a Murine Model of Malignant 15.2 H Kindler 1345 15.3 D Baratti 1400 15.4 J Leinwand 1415 15.5 V Kepenekian 1430 Integrating Systemic Therapy and Novel Therapeutics for Periteal Malignant Malignant Periteal : Incorporati of Novel Pathological Grading into a Recently Proposed TNM Classificati Improves Outcome Predicti Tissue Platinum Localizati in Multimodal Intraperiteal Chemotherapy for Malignant Periteal Role of Systemic Perioperative Chemotherapy in Diffuse Malignant Periteal Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperiteal Chemotherapy (HIPEC): A Multi- Institutial Study 16.2 J Friedberg 1345 The State of the Art Technique for Extrapleural Pneumectomy The State of the Art Technique for Lung-Sparing Surgery 16.3 D Waller 1400 Persalising Surgery 16.4 W Weder 1415 16.5 R Rintoul 1430 Save the Lung or Take the Lung? Advantages and Disadvantages of Extrapleural Pneumectomy and Pleurectomy/Decorticati MesoVATS: Where Do We Go From Here? 14.6 S Snedd 1445 Understanding the Mutatis of Malignant (MM): A Study of Mouse Homologues of Human MM 15.6 Chairs 1445 Discussi 16.6 M Culligan 1445 Complicatis of Extended Pleurectomy/Decorticati vs. Extrapleural Pneumectomy in 138 Patients Undergoing Surgery for MPM 1500 Tea/Poster Viewing 1500 Tea/Poster Viewing 1500 Tea/Poster Viewing 17 Multimodality 1 1530 P Baas 18 Nursing and Supportive Care 1530 L Darlis 19 Biomarkers 1 1530 J Creaney L Lang-Lazdunski M Hesdorffer O Roe 17.1 W Buikhuisen Maintenance Therapy after First- 1530 Line Treatment 18.1 M Hesdorffer Promoting Entry into Clinical Trials and 1530 Improving Access to Specialist Treatment and Care 19.1 R Bueno Molecular Prognostic Factors in 1530 Practice

17.2 I Opitz 1545 17.3 W Weder 1600 17.4 R Bueno 1615 17.5 J Friedberg 1630 17.6 Roundtable Discussi 1645 Intraoperative Adjuvant Therapies for MPM: Worthwhile or Waste of Time? Hemithoracic Radiotherapy after Neoadjuvant Chemotherapy and EPP: Final Results of the Randomized Phase II Trial SAKK 17/04 Neoadjuvant Therapy and Surgery Radical Pleurectomy and Intraoperative Photodynamic Therapy for the Treatment of Epithelial MPM Best Approach for Patients with Unresectable MPM Poster Discussi Sessi Periteal Animal Models Free Evening 18.2 L Darlis 1545 18.3 M Culligan 1600 18.4 P Magabanyane 1615 18.5 A Scherpereel 1630 18.6 L Reinstein 1645 Improving Outcomes in : An Internatial Approach to Meeting Nurses Educatial Needs Developing and Coordinating a Specialist Program of Treatment and Care Palliative Care in Kuruman: Setting Up a Community Oasis Pulmary Rehabilitati at Home is Feasible and Exhibits Significant Benefits in Patients with MPM Treated by Chemotherapy 19.2 R Cornelissen 19.3 J van Meerbeeck 1545 19.4 S Kao 1615 19.5 D Jean 1630 Intratumoral Macrophage Phenotype and CD8+ T Lymphocytes Predict Local Tumor Outgrowth at the Interventi Site in MPM 1600 A Breath Test for Diagnosing MPM Importance of Supportive Resources for Patients and Caregivers 19.6 N Maskell 1645 SWAMP Trial Poster Discussi Sessi Biomarkers Free Evening Expressi of Secreted Protein Acidic and Rich in Cysteine (SPARC) in MPM is Associated with Short Survival TERT Promoter Mutatis in MPM: Strg Associati with Sarcomatoid Histological Subtype Poster Discussi Sessi Asbestos Issues Imaging Free Evening

Day 2-23 October 2014 20 Medallists' Plenary 0800 A Linegar S Mutsaers 20.1 M-C Jaurand 0800 Cell Lines and Animal Models 20.2 B Robins 0830 Biomarkers and Immunotherapy 20.3 S Albelda 0900 20.4 21 Wagner Medallist 2014 Molecular Genetics 21.1 K Birnie 1030 21.2 S Maki- Nevala Immunogene Therapy for : The Lg and Winding Road 0930 Title to be announced 1000 Coffee/Poster Viewing 1030 M Carbe 22 1045 21.3 T Seiwert 1100 21.4 Y Sekido 1115 21.5 D Barbe 1130 21.6 M Phillips 1145 Novel Therapeutics 1030 D Fennell 23 Epidemiology 2 1030 G Nels Y Sekido R Kratzke J tewaternaude Loss of mir-223 and Over-Expressi of Target Protein Stathmin Regulate Cell Motility in Malignant Exome Sequencing Reveals Novel Recurrent Mutatis in Asbestos-Exposed Lung Adenocarcinoma and Malignant Genomic Profiling of Malignant Reveals Comm BAP1, CDKN2A/B, NF2, and INPP4B Aberratis, but a Paucity of Targetable Changes Hippo Pathway Inactivati in Malignant Cells The Dual PI3K/mTOR Inhibitor GDC- 0980 Bypasses Multicellular Resistance of Spheroids 22.1 D Fennell 1030 Novel Therapeutics 23.1 J McCullough 1030 22.2 S Albelda 1045 22.3 R Salgia 1100 22.4 L Mutti 1115 22.5 A Clive 1130 Tumor-Associated Macrophages Mediate Resistance to Pegylated Arginine Deiminase in MPM 22.6 D Schrump 1145 21.7 V Ascoli 1200 BAP1 Analysis in Familial 22.7 G Reid 1200 Histamine Dihydrochloride in the Treatment of Role of Focal Adhesi Kinase (FAK) Inhibiti in CAIX Inhibitors: Targeting Metabolism The Bristol Randomised Ctrolled Trial of Zoledric Acid in Malignant Pleural Disease: A Proof of Principle, Pilot Study Mithramycin Induces DNA Damage, Depletes Sp1 and Activates p53 Signaling to Mediate Senescence and Autophagy of MPM Cells In Vitro and In Vivo TargomiRs: Targeted Delivery of a Novel MicroRNA Mimics as an Approach to Treating MPM 23.2 J Phillips 1045 23.3 R Jes 1100 23.4 N van Zandwijk 1115 23.5 V Panou 1130 23.6 D Kielkowski 1145 23.7 H Fevzi Batirel 1200 Asbestos Blues: A History of Asbestos Mining in South Africa The South African Legacy of Asbestos: Then and Now Ctaminati of the South African Envirment from Asbestos Mining and Related Activities in Australia: Data from the Australian Registry Overrepresentati of Malignant Periteal amg Females in a Cohort of 296 Danish Patients Mortality in a Cohort Born in the Early 20th Century in the Prieska District, South Africa Asbestos Ctrol Strategic Plan in Turkey's Determinati of the Magnitude of the Problem

21.8 M Carbe 1215 BAP1 Mutatis in Sporadic 22.8 L Moro 1215 Agist Activati of Estrogen Receptor Beta Sensitizes MPM Cells to Cisplatin Cytotoxicity 23.8 S Burgers 1215 Occasial Exposure to Asbestos: What is the Risk? 24 Persalised Therapy Symposium 1230 Lunch/Poster Viewing 1230 Lunch/Poster Viewing 1230 Lunch/Poster Viewing 1330 B Robins 25 Multimodality 2 1330 D Waller 26 Optimising Radiotherapy 1330 R Abratt J Steele J Sorensen C Sime 24.1 D Barbe 1330 Spheroids and Drug Sensitivity 25.1 S Burgers 1330 24.2 C Alifrangis 1345 24.3 G Middlet 1400 24.4 B Robins 1415 Drug Resistance or Sensitivity: How to Use Molecular Events to Pick Therapy Signalling: Why D t the TKIs or Antiangiogenesis Agents Work Well? Immunological Therapy: Who and How to Treat Based Likely/Unlikely Respses 25.2 I Opitz 1345 25.3 I Opitz 1400 25.4 S Bolukbas 1415 Combining Chemotherapy and/or Radiati with Surgery, Before, After, Never or Both: Ratiale and Evidence Multimodality Benefit Score: Improved Patient Selecti for MPM Patients Undergoing Surgery after Inducti Chemotherapy Phase I Intracavitary Cisplatin-Fibrin Chemotherapy after Resecti for MPM Patients (INFLuenCe-Meso) Predictors of Survival and Progressi-Free Survival after Radical Pleurectomy followed by Chemotherapy for Epithelioid MPM 26.1 C Sime 1330 26.2 A Rimner 1345 26.3 K Cengel 1400 26.4 M De Perrot 1415 Radiorespsiveness, Ratiale, and Roles for Radiati Therapy for Radiotherapy Techniques and Outcomes after Radical Pleurectomy for Future Horizs for Radiati Therapy for : Radiobiology and Immunotherapy Neoadjuvant Radiati Therapy in Patients Receiving Extrapleural Pneumectomy 24.5 L Schunselaar 1430 Primary Tumor Cultures of MPM for Multiple Drug Testing 25.5 A Sharkey 1430 Does the Timing of Chemotherapy Affect Outcome following Radical Surgery for MPM? 26.5 C Sime 1430 Prophylactic Irradiati of Surgical Tract Sites for MPM in the Era of Radical Pleurectomy 24.6 J Quispel- Janssen 1445 Persalized Treatment for Patients with MPM Based Primary Tumor Cultures 25.6 W Weder 1445 Perioperative Outcome for Patients Undergoing Inducti Chemotherapy followed by EPP Compared to P/D 26.6 Chairs 1445 Discussi 1500 Tea/Poster Viewing 1500 Tea/Poster Viewing 1500 Tea/Poster Viewing 27 Clinical Trials 1530 H Kindler 28 Biomarkers 2 1530 S Knuutila 29 Pathology 1530 M-C Jaurand A Scherpereel J van Meerbeeck J Murray

27.1 P Baas 1530 FAK Inhibitor VS-6063 (Defactinib) Targets Cancer Stem Cells which are Enriched by Standard of Care Chemotherapy 28.1 J Creaney 1530 Challenges in Development of Biomarkers 29.1 A Hjerpe 1530 Discussis Guidelines for Cytopathologic Diagnosis of Malignant 27.2 M Keegan 1545 Determinati of Biomarker Respse in a Phase II Window of Opportunity Study of Defactinib (VS-6063), a Focal Adhesi Kinase (FAK) Inhibitor, in Subjects with Resectable MPM 28.2 A Lint 1545 A Prognostic Index for Estimating Survival in a Large Series of Patients with MPM 29.2 N Vorajee 1545 Pathalogical Challenges in the Diagnosis of Pleural Malignant 27.3 P Szlosarek 1600 27.4 A Mansfield 1615 27.5 A Cook 1630 27.6 H Kindler 1645 Phase I Study of ADI-PEG 20 in Combinati with Pemetrexed and Cisplatin (TRAP) in Patients with Malignant Systematic Review of Respse Rates of Sarcomatoid MPMs in Clinical Trials Immunological Effects of the Glucocorticoid Dexamethase in the Ctext of Chemoimmunotherapy for Multi-Arm, N-Randomized, Open- Label Phase Ib Study to Evaluate FP- 1039/ GSK3052230 Given in Combinati with Standard-of-Care Chemotherapy Regimens in NSCLC and MPM with Deregulated FGF Pathway Signaling Poster Discussi Sessi 28.3 C Blanquart 1600 28.4 S Albelda 1615 28.5 M Kirschner 1630 28.6 R Hassan 1645 Study of the Chemokine CCL2 in MPM Cellular Interfer Respse as a Predictor of Chemosensitivity Use of a 6-microRNA Signature for Prognosis in MPM Successful Implementati of a Comprehensive Bio- Specimen Bank for Poster Discussi Sessi 29.3 F Galateau- Salle 1600 29.4 R Rintoul 1615 29.5 D Jean 1630 29.6 T Chernova 1645 MESOBANK: A Clinicobiological Database for Epidemiological and Translatial Research for MESOBANK UK: An Internatial Bioresource for Tissue Double Inactivati of NF2 and LAST2, Members of the Hippo Pathway, in a Tumor Subgroup of MPMs Lg-Fibre Carb Nanotubes and Asbestos- Induced Pleural Lesis Exhibit a Comm Molecular Signature Poster Discussi Sessi Novel Therapies Pathology Epidemiology Gala Dinner Kirstenbosch Gala Dinner Kirstenbosch Gala Dinner Kirstenbosch

Day 3-24 October 2014 31 Social Advocacy 31.1 K Ruff 0800 31.2 R Spoor 0815 31.3 S Kao 0830 31.4 M Hindry 0845 31.5 S Kisting 0900 31.6 M Hesdorffer 0800 L Kazan-Allen 32 Surgery & Staging 1 0800 R Bueno 33 Immunology 0800 T Nakano P Camay S Bolukbas S Albelda 0915 31.7 S Kazan 0930 31.8 E Algotss 0945 The Critical Role Scientists and Health Professials Can Play to Prevent Asbestos-Related Harm: Recent Examples and Lesss Learned Limitatis the Right to Legal Recourse for Victims in South Africa Mortally Wounded : Stakeholder Perceptis of the MPM Diagnostic Process The Role of Victims Associatis for Preventi and Compensati of Asbestos Diseases Community Perspectives Compensati for Asbestos- Related Diseases, including, in South Africa The Voice of the Patient in the United States: Advocacy Efforts and Accomplishments of the Applied Research Foundati Patients Rights to Compensati from United States Asbestos Bankruptcy Trust Funds: An Update Asbestos Ctaminati at Khiba School: Possible Legal Interventis 32.1 A Sharkey 0800 32.2 E Alley 0815 32.3 O Mercier 0830 32.4 W Richards 0845 32.5 S Bolukbas 0900 32.6 S Hasegawa 0915 How Useful are Subjective Variables in Predicting Outcome of Radical Surgery for MPM? Posterior Intercostal Lymph Nodes Affect Prognosis for Surgery-Based Treatment of MPM and Should Be Csidered N2 Lymph Nodes Factors Affecting Survival after Extrapleural Pneumectomy for pn2 MPM Does Neoadjuvant Chemotherapy Improve Overall Survival Amg Patients with Pathological N2-N3 MPM Who Undergo Surgical Resecti? Abdominal Recurrence in Patients Undergoing Lung-Sparing Radical Pleurectomy and Macroscopic Complete Resecti for MPM Outcome of 104 Csecutive Surgical Candidates with MPM: A 10-Year Experience at Hyogo College of Medicine 32.7 Chairs 0930 Poster Discussi 33.7 33.1 D Sterman 0800 33.2 L Mutti 0815 33.3 W Lesterhuis 0830 33.4 L Wu 0845 33.5 S Kao 0900 33.6 T Seiwert 0915 J van Meerbeeck 0930 33.8 E Mo 0945 A Phase I/II Clinical Trial Evaluating Two Different Chemotherapy Regimens in Combinati with Intrapleural Adenoviral-Mediated Interfer- Alpha (SCH 721015, Ad.hIFNa2b) Gene Transfer for MPM Anti-CTLA4 Checkpoint Blockade in Patients with Improving Immune Checkpoint Blockade Efficacy in : A Systems Biology Approach Tumor-Infiltrating Regulatory T Cells after Local Radiati Can Be Reversed by Systemic Blockade of the Immune Checkpoints in Murine Programmed Death Ligand 1 (PD-L1) Expressi is an Independent Adverse Prognostic Factor in MPM T-Cell Inflamed Phenotype, PD- L1, and ICOS Expressi Identify a Subgroup of Malignant s Potentially Amenable to Immunotherapy Approaches Expressi of Immune Checkpoint Programmed Death 1 and its Ligands MPM Cells A PD1-CD28 Switch Receptor is Able to Augment Mesothelin- Directed Chimeric Antigen Receptor T-Cell Therapy in a Resistant In Vivo Model of Human Tumor

1000 Coffee 1000 Coffee 1000 Coffee 34 Imaging 1030 S Armato 35 34.1 A Nowak 1030 34.2 R Gill 1045 34.3 J Coolen 1100 34.4 S Armato 1115 Surgery & Staging 2 1030 D Sugarbaker 36 Molecular Therapeutics 1030 L Mutti J Coolen H Fevzi Batirel P Szlosarek Assessing Treatment Respse in 2014: How Should We Deal with Immunotherapy, PET, and Biomarkers? Preliminary Assessment of Apparent Diffusi Coefficient in Biphasic MPM by Diffusi- Weighted MRI (DWI) Evaluati of Early Chemotherapy Respse and Outcome of Inoperable MPM Patients by Diffusi-Weighted MRI CT-Based Tumor Volume: Correlati with Surgical Volume 35.1 L Lang- Lazdunski 1030 35.2 S Bolukbas 1045 35.3 R Camer 1100 35.4 G Frendl 1115 Pleurectomy/Decorticati, Hyperthermic Pleural Lavage with Povide-Iodine, Prophylactic Radiotherapy and Systemic Chemotherapy: Experience in 100 Csecutive Patients Pretreatment Score Correlates with Outcomes in Patients Undergoing Lung-Sparing Multimodality Treatment Aerosolized Combinati of CoSeal and Autologous Blood Helps Reduce Air Leaks following Pleurectomy for Incidence and Risk Factors for Venous Thromboembolism in Patients with MPM in the Postoperative Period: A 4-Year Retrospective Analysis 36.1 M Keegan 1030 36.2 F Pentimalli 1045 36.3 V Serre- Beinier 1100 36.4 J Creaney 1115 The Cancer Stem Cell Inhibitors VS-6063 (Defactinib) and VS- 5584 Exhibit Synergistic Anticancer Activity in Preclinical Models of Reactivating RBL2/p130 Oncosuppressive Functi as a New Possible Therapeutic Strategy for Pleural Involvement of MIF Signaling in Malignant Identificati of Neo-Antigens using Whole Exome Sequencing in a Murine Model of 34.5 S Armato 1130 Toward Volumetric Respse Criteria for 35.5 H Kindler 1130 IMIG/IASLC Staging 36.5 M MacFarlane 1130 Targeting Cell Death Pathways in Preclinical Models of MPM 34.6 C Straus 1145 Natural History Tumor Volume Growth as a Ctributory Factor in Assessing Respse to Chemotherapy in MPM 35.6 R Gill 1145 North American Multicenter Feasibility Trial of Volumetric CT for the Clinical Staging of MPM 36.6 M Locke 1145 Targeting Resistance to Arginine Depleti Therapy in 40 Closing Plenary 1200 D Fennell 1215 J tewaternaude Welcome to imig2016 1230 Lunch & B Voyage